CELLINK AB has appointed an Advisory Board
CELLINK AB (“CELLINK” or the “Company”) has appointed an Advisory Board to assist the company in strategic development, the Advisory board is composed of four individuals with extensive experience in their fields of expertise. See members below.
Dr. David Williams is a Professor in the Institute of Regenerative Medicine at Wake Forest School of Medicine and is regarded as a leading authority on biomaterials, medical devices, and biocompatibility. Dr. Willams has authored and co-authored over 400 technical papers within his field of expertise. Dr. Willams will advise CELLINK in the development of new Bioinks.
Dr. Ali Khademhosseini, MASC, is a Professor at the Harvard-MIT’s Division of Health Sciences and Technology (HST), Brigham and Women’s Hospital and Harvard Medical School. He also leads a satellite laboratory at the World Premier International-Advanced Institute for Materials Research at Tohoku University, Japan. Dr. Khademhosseini will be advising CELLINK on bioprinting technologies.
Dr. Erik Ingelsson is a Professor of Medicine at Stanford University. His research areas are cardiovascular medicine with focus on metabolic disorders such as obesity and insulin resistance, and their role in the development of cardiovascular disease. Dr. Ingelsson will advise CELLINK in application development of CELLINKs’ products and services.
Mr. Rolf Classon has extensive experience holding executive positions in the biotechnology sector. Mr. Classon has been the Chairman of the Executive Committee of Bayer HealthCare AG, CEO of Bayer Daignostics, executive management positions within Pharmacia, a director of Hill-Rom Corporation, Chairman of Tecan Group Ltd., and a member of Fresenius Medical. Mr. Classon will advise the company in strategic and operational matters within his area of expertise.
For further information, please contact:
This information is such information as CELLINK AB is obligated to publish under EU Market Abuse Regulation. The information was submitted for publication on March 17, 2017 at. 15:30 CET.
CELLINK has created one of the world’s first universal Bioinks currently used by many of the world’s most renowned research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in 3D-Bioprinters. CELLINKs universal Bioink show excellent results and can be used in both CELLINKs proprietary 3D Bioprinters and its’ competitors. Mangold Fondkommission AB, Phone: +46 8 5030 1550, the Certified Adviser.